- Home
- AVY vs PODD Comparison
AVY vs PODD Comparison
Compare AVY & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVY
- PODD
- Stock Information
- Founded
- AVY 1935
- PODD 2000
- Country
- AVY United States
- PODD United States
- Employees
- AVY N/A
- PODD N/A
- Industry
- AVY Containers/Packaging
- PODD Medical/Dental Instruments
- Sector
- AVY Consumer Discretionary
- PODD Health Care
- Exchange
- AVY Nasdaq
- PODD Nasdaq
- Market Cap
- AVY 15.1B
- PODD 16.5B
- IPO Year
- AVY N/A
- PODD 2007
- Fundamental
- Price
- AVY $192.48
- PODD $276.08
- Analyst Decision
- AVY Buy
- PODD Buy
- Analyst Count
- AVY 12
- PODD 16
- Target Price
- AVY $233.63
- PODD $271.19
- AVG Volume (30 Days)
- AVY 566.6K
- PODD 533.0K
- Earning Date
- AVY 01-30-2025
- PODD 02-20-2025
- Dividend Yield
- AVY 1.83%
- PODD N/A
- EPS Growth
- AVY 40.44
- PODD 235.68
- EPS
- AVY 8.33
- PODD 5.74
- Revenue
- AVY $8,680,500,000.00
- PODD $1,983,900,000.00
- Revenue This Year
- AVY $5.94
- PODD $23.56
- Revenue Next Year
- AVY $4.75
- PODD $18.07
- P/E Ratio
- AVY $23.08
- PODD $48.28
- Revenue Growth
- AVY 4.84
- PODD 27.42
- 52 Week Low
- AVY $181.99
- PODD $160.19
- 52 Week High
- AVY $233.48
- PODD $282.86
- Technical
- Relative Strength Index (RSI)
- AVY 52.94
- PODD 61.28
- Support Level
- AVY $189.54
- PODD $260.84
- Resistance Level
- AVY $193.55
- PODD $274.45
- Average True Range (ATR)
- AVY 3.37
- PODD 7.63
- MACD
- AVY 1.24
- PODD 0.86
- Stochastic Oscillator
- AVY 87.56
- PODD 75.49
About AVY Avery Dennison Corporation
Avery Dennison manufactures pressure-sensitive materials, merchandise tags, and labels. The company also runs a specialty converting business that produces radio-frequency identification, or RFID, inlays and labels. Avery Dennison draws a significant amount of revenue from outside the United States, with international operations accounting for the majority of total sales.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.